Aptar Reports Strong Start to the Year with Impressive Q1 Results

Aptar (ATR) reported a 5% growth in core sales and a significant 30% increase in adjusted EPS to $1.26 in the first quarter. The Pharma segment showed strong performance, while the Beauty segment maintained stable sales. Aptar anticipates Q2 adjusted EPS to range from $1.30 to $1.38 and is focused on enhancing shareholder value through strategic investments and cost management.